Madrigal Pharmaceuticals, Inc. MDGL Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s investment proceeds?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported investment proceeds of $353.87M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s investment proceeds changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s investment proceeds increased by 20.1% year-over-year, from $294.69M to $353.87M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s investment proceeds has grown at a 29.2% compound annual growth rate (CAGR), from $389.27M to $1.08B.
- What does investment proceeds mean?
- Cash received from selling or maturing financial investments.
- How do you interpret investment proceeds?
- Higher inflows indicate the conversion of treasury assets into cash, often used to fund ongoing R&D or operational burn.
- How does investment proceeds compare across companies?
- Standard for companies managing liquidity through investment portfolios.